Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin
Figure 1
Gel electrophoresis of the products coming from the incubation of the wild-type topoisomerase I with the [γ-32P] end-labelled duplex DNA, shown at the top of the figure in the absence (lanes 2-3) or presence (lanes 4–10) of increasing amounts of CPT. The arrow at the DNA sequence indicates the CL1 site preferred by the wild-type protein. Lanes 11 and 12 and 13–19 show the same experiment with the Asp677Gly-Val703Ile mutant.
